Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Change in Accured Expenses (2021 - 2025)

Historic Change in Accured Expenses for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $1.1 million.

  • Amylyx Pharmaceuticals' Change in Accured Expenses rose 10835.24% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$31.8 million, marking a year-over-year decrease of 15139.6%. This contributed to the annual value of -$59.8 million for FY2024, which is 37693.66% down from last year.
  • As of Q3 2025, Amylyx Pharmaceuticals' Change in Accured Expenses stood at $1.1 million, which was up 10835.24% from $5.4 million recorded in Q2 2025.
  • In the past 5 years, Amylyx Pharmaceuticals' Change in Accured Expenses registered a high of $20.8 million during Q4 2023, and its lowest value of -$26.4 million during Q4 2024.
  • Over the past 5 years, Amylyx Pharmaceuticals' median Change in Accured Expenses value was $1.1 million (recorded in 2025), while the average stood at -$1.3 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first crashed by 887945.21% in 2024, then skyrocketed by 14308.4% in 2025.
  • Quarter analysis of 5 years shows Amylyx Pharmaceuticals' Change in Accured Expenses stood at $13.0 million in 2021, then tumbled by 56.61% to $5.7 million in 2022, then skyrocketed by 267.58% to $20.8 million in 2023, then plummeted by 227.07% to -$26.4 million in 2024, then skyrocketed by 104.15% to $1.1 million in 2025.
  • Its Change in Accured Expenses stands at $1.1 million for Q3 2025, versus $5.4 million for Q2 2025 and -$11.9 million for Q1 2025.